We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.20 | 2.00 | 2.40 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMODX
RNS Number : 1418J
Omega Diagnostics Group PLC
03 December 2018
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
INTERIM RESULTS
FOR THE SIX MONTHSED 30 SEPTEMBER 2018
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces its unaudited interim results for the six months ended 30 September 2018.
Omega is one of the UK's leading companies in the fast growing area of food intolerance testing and also operates in markets supplying tests for allergies and autoimmune diseases and specific infectious diseases through a strong distribution network in over 100 countries.
Following the closure of our German business unit and the Pune manufacturing facility in India together with the disposal of our infectious disease business, we now have a smaller business focused on long term profitability and prioritised to deliver on VISITECT(R) CD4, Allergy and Food Intolerance. The results below reflect the reshaping of Omega.
Financial Highlights:
-- Revenue reduced by 27% at GBP5.23m (2017: GBP7.11m) -- Revenue from continuing operations reduced by 7% at GBP4.22m (2017: GBP4.54m) -- Gross margin decreased by 2.9% on the same period last year at 60.2% (2017: 63.1%) -- Statutory profit before tax of GBP0.8m (2017: GBP0.1m) -- Adjusted loss before tax(1) of GBP0.51m (2017: adjusted profit before tax of GBP0.22m) -- Adjusted earnings per share(1) of -0.5p (2017: 0.3p) -- Bank overdraft at the period end of GBP0.45m (2017: cash of GBP2.42m)
-- Food Intolerance revenue increased by 12% to GBP3.84m as compared to the immediately prior 6 month period (H2 FY18: GBP3.42m)
-- Omega GmbH liabilities of GBP0.7m written back following appointment of a permanent administrator on 1 September 2018
(1) Adjusted for exceptional items, amortisation of intangible assets and share based payment charges
Operational Highlights:
-- Strategic review leading to:
o the closure of our German business unit and the Pune manufacturing facility in India
o the disposal of our legacy Infectious disease business to Lab 21 Healthcare Ltd for up to GBP2.175 million with a gain on sale of GBP1.09m
-- 60 allergens CE marked to run on the IDS automated instrument and first purchase order received from IDS
-- Visitect(R) CD4 350 cut off test commercialisation activities progressing with distributor agreements signed for Nigeria, Zimbabwe, Ghana, Zambia, Kenya, Columbia, Indonesia, Guatemala, Cameroon, Uruguay and Brazil with agreements under negotiation covering a further five countries
-- Visitect(R) CD4 Advanced Disease test (utilising a lower 200 cut-off) validation is ongoing and the project continues to progress on track
Regarding outlook, David Evans, Chairman, said:
"Our short-term outlook is dominated by our efforts to realise value for Shareholders whilst at the same time successfully accelerating our efforts to commercialise our CD4 offering. The challenges are not inconsequential but I remain confident that in those areas where we can control our own destiny that we will succeed in delivering our objectives. In those areas where we are not masters of our own destiny then, by definition, the outcome will always be less certain. I believe it is best for our statement to reflect that reality as it stands today. Rest assured we will continue to work towards achieving success for all our Stakeholders."
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Hot Features
Premium
Omega Diagnostics Group PLC Tel: 01259 763 030
David Evans, Non-Executive Chairman www.omegadiagnostics.com
Colin King, Chief Executive
Kieron Harbinson, Group Finance
Director
Mob: 07740 084452
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/James Thompson (Corporate
Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
Chairman's Statement
Financial performance
Total revenue for the six months ended 30 September 2018 reduced by 27% to GBP5.23m (2017: GBP7.11m) with much of the reduction being attributable to the divestment of our legacy infectious disease division and the decision to close our German manufacturing facility, limiting the revenue contribution from both these units to Q1 only within the reporting period. Revenue from continuing operations reduced by 7% to GBP4.22m (2017: GBP4.54m) predominantly due to the reduction in Food Intolerance revenue as described below.
Food Intolerance revenue decreased by 7% to GBP3.84m over the same H1 period in the prior year (2017: GBP4.13m) but showed an increase of 12% when measured against the most immediate six-month period being H2 in the year to 31 March 2018 (GBP3.84m v GBP3.42m). Sales of our FoodPrint(R) laboratory system were GBP2.30m (2017: GBP2.60m) with the difference attributable to the ordering pattern of our largest customer which stockpiled in the prior half-year period, which was not repeated in the current period. We maintained sales of Food Detective(R) at GBP0.95m, the same level as in the prior period, with an uplift in three key markets offsetting the loss of GBP0.23m of sales of the retail kit version in the prior period due to the previously reported regulatory issue which is still in the process of being resolved.
Sales in both the Allergy/Autoimmune and Infectious disease divisions declined by 53% and 54% respectively due to the divestment/closure decisions referred to above, with Allergy/Autoimmune sales of GBP0.79m (2017: GBP1.67m) and Infectious disease sales of GBP0.60m (2017: GBP1.31m).
Gross profit was GBP3.15m (2017: GBP4.49m) with the gross margin percentage reducing by 2.9 percentage points to 60.2% (2017: 63.1%). The reduction in margin is due to product mix and the fixed element of manufacturing labour cost against the lower level of sales in the period. The adjusted loss before tax was in line with management's expectation at GBP0.51m (statutory profit before tax of GBP0.82m less the exceptional credit items of GBP1.45m and adding back amortisation of intangibles and share-based payment charges totalling GBP0.12m) (2017: adjusted profit before tax of GBP0.22m). When analysed in each of the first two quarters, there was an adjusted loss before tax in Q1 of GBP0.87m, followed by an adjusted profit before tax in Q2 of GBP0.36m. Q1 included non-recurring losses of GBP0.25m related to the German and Indian business units, underpinning the reason behind their closure.
A tax charge of GBP0.1m resulted from the sale of the legacy infectious disease business versus a tax credit of GBP0.1m in the prior period resulting in adjusted earnings per share of -0.5p (2017: 0.3p). Statutory basic earnings per share were 0.9p (2017: 0.2p) due to the exceptional items noted below.
Exceptional items
We have reported two exceptional credits in the period; the sale of our legacy infectious diseases business to Lab 21 Healthcare Ltd on 28 June 2018, for up to GBP2.175m, yielded a book profit in the period of GBP1.09m, being the balance of the sale proceeds in excess of the book value of assets transferred and; following the decision to close the German operation, the assets as at 31 March 2018 were fully provided against and this was reported in our final results announcement dated 6 August 2018. Since formal insolvency proceedings commenced with Omega GmbH on 1 September 2018, the Group is no longer liable for any of the liabilities and this has resulted in a credit of GBP0.36m through the profit and loss account and a credit of GBP0.32m through other comprehensive income. There has been a corresponding reduction in the reported value of long term borrowings on the balance sheet to reflect this. Both of these items are excluded from the adjusted loss before tax for the period.
Strategic review
Since the commencement of a strategic review in the last financial year, the Board has prioritised to deliver on VISITECT(R) CD4, Allergy and Food Intolerance, following the divestment of the infectious disease business and the closure of operations in Germany and India.
Visitect(R) CD4
The Company continues to make good progress with the commercialisation plans for the VISITECT(R) CD4 350 cut-off test. Two additional distribution agreements have been signed since the trading update dated 10 October 2018. Country coverage now extends to 11 countries; Nigeria, Zimbabwe, Ghana, Zambia, Kenya, Columbia, Indonesia, Guatemala, Cameroon, Uruguay and Brazil with negotiations ongoing in a further five countries.
The VISITECT(R) CD4 Advanced Disease test (utilising a lower 200 cut-off) continues to make good progress. Since the trading update a third validation batch has been manufactured and is currently being externally tested in India. Although still to be finalised, external results completed to date for all three validation batches are looking promising. We now have ethical approval in place to start our performance evaluation studies with initiation planned as soon as the ongoing site training has been successfully completed.
Discussions are ongoing with key HIV stakeholders to formulate plans for the procurement and implementation of VISITECT(R) CD4 Advanced Disease in low and middle-income countries at the earliest opportunity. Up to 40% of patients diagnosed with HIV are already at an advanced stage of the disease. Identification of advanced HIV disease is a critical issue that can improve the effectiveness of HIV control measures and it is widely recognised by opinion leaders that utilisation of the VISITECT(R) CD4 Advanced Disease test will play an important role in ensuring patients receive the most appropriate package of care.
Allergy
Since signing the distribution agreement with Imuunodiagnostics Systems ('IDS') in April of this year, we have continued to develop allergens for IDS' automated instrument. Since our last allergy update announced on 27 September 2018, we have CE-Marked two additional allergens, extending the menu to 60 allergens in total. We have also now shipped our first order to IDS and anticipate one further order for the final quarter of this financial year. We are working closely with IDS and there is regular contact between our respective commercial teams. We will continue to support IDS during the launch phase for this product range.
Food Intolerance
We are encouraged with the sales result from our Food Intolerance division for two reasons; sales for the six months to 30 September 2018 recorded growth of 12% when measured against the immediately prior six-month period to 31 March 2018 and; sales of Food Detective(R) of GBP0.95m for the six months to 30 September 2018 were equivalent to H1 in the prior period, despite that prior period including sales of GBP0.23m for the retail kit version which did not repeat in the current period due to the ongoing regulatory issue. We continue to work with our notified body on how best to resolve the issue.
The commissioning of a new 35,000 sq. ft facility is proceeding to plan with an expected move during the middle of the next calendar year. The upgraded facility underpins our view that the food intolerance division offers longer term growth opportunity, particularly in the US and China, and the Board continues to explore how best to realise value from this division given its stage in its current life-cycle.
Outlook
Our short-term outlook is dominated by our efforts to realise value for Shareholders whilst at the same time successfully accelerating our efforts to commercialise our CD4 offering. The challenges are not inconsequential but I remain confident that in those areas where we can control our own destiny that we will succeed in delivering our objectives. In those areas where we are not masters of our own destiny then, by definition, the outcome will always be less certain. I believe it is best for our statement to reflect that reality as it stands today. Rest assured we will continue to work towards achieving success for all our Stakeholders.
David Evans
Non-Executive Chairman
30 November 2018
Consolidated Statement of Comprehensive Income
for the six months ended 30 September 2018
6 month period ended 6 month period ended
30 September 2018 30 September 2017
----------------------------------------- -----------------------------------------
Continuing Discontinued Continuing Discontinued
Notes operations operations Total operations operations Total
GBP GBP GBP GBP GBP GBP
Revenue 3 4,224,889 1,002,646 5,227,535 4,535,219 2,578,116 7,113,335
Cost of sales (1,618,225) (464,136) (2,082,361) (1,372,712) (1,250,265) (2,622,977)
------------ ------------- ------------ ------------ ------------- ------------
Gross profit 2,606,664 538,510 3,145,174 3,162,507 1,327,851 4,490,358
Administration
costs (2,405,656) (440,874) (2,846,530) (2,721,495) (616,729) (3,338,224)
Selling and
marketing
costs (765,626) (195,205) (960,831) (617,231) (451,348) (1,068,579)
Other operating
income 61,026 - 61,026 15,707 - 15,707
------------ ------------- ------------ ------------ ------------- ------------
Operating (loss)/profit
before exceptional
items (503,592) (97,569) (601,161) (160,512) 259,774 99,262
Exceptional
items:
Gain on sale of legacy
infectious disease
business 1,091,808 - 1,091,808 - - -
Omega GmbH
liabilities
write off 358,819 - 358,819 - - -
------------
Operating profit after
exceptional items 947,035 (97,569) 849,466 (160,512) 259,774 99,262
Finance costs 4 (25,599) - (25,599) (27,061) - (27,061)
Finance revenue
-
interest
receivable 11 - 11 480 - 480
------------ ------------- ------------ ------------ ------------- ------------
Profit before
taxation 921,447 (97,569) 823,878 (187,093) 259,774 72,681
Tax (charge) /
credit 5 (102,324) - (102,324) 96,267 - 96,267
Profit for the
period 819,123 (97,569) 721,554 (90,826) 259,774 168,948
Other comprehensive income to be reclassified
to profit and
loss
in subsequent
periods
Exchange differences on
translation of foreign
operations 30,605 - 30,605 83,215 - 83,215
Exceptional item-Omega
GmbH liability write
off 317,294 - 317,294 0 - -
Tax charge 5 (5,124) - (5,124) (15,160) - (15,160)
------------ ------------- ------------ ------------ ------------- ------------
Other comprehensive
income
for the period 342,775 - 342,775 68,055 - 68,055
Total comprehensive
income
for the period 1,161,898 (97,569) 1,064,329 (22,771) 259,774 237,003
------------ ------------- ------------ ------------ ------------- ------------
Earnings Per
Share
(EPS)
Basic EPS on
profit
for the period 6 0.6p 0.2p
Diluted EPS on
profit
for the period 0.6p 0.1p
Adjusted Profit before Taxation
6 month period ended 6 month period ended
30 September 2018 30 September 2017
----------------------------------------- ------------------------------------
Continuing Discontinued Continuing Discontinued
operations operations Total operations operations Total
GBP GBP GBP GBP GBP GBP
Profit before
taxation 921,447 (97,569) 823,878 (187,093) 259,774 72,681
Exceptional
items (1,450,627) - (1,450,627) - - -
Amortisation
of
intangible
assets 65,474 24,573 90,047 59,128 59,217 118,345
Share-based
payment
charges 30,000 - 30,000 26,895 - 26,895
Adjusted
(loss)/profit
before
taxation (433,706) (72,996) (506,702) (101,070) 318,991 217,921
------------ ------------- ------------ ----------- ------------- --------
Earnings Per
Share (EPS)
Basic and
diluted
Adjusted
EPS on
profit for
the
period 6 (0.5p) 0.3p
Adjusted (loss) / PBT stated before exceptional items, amortisation of intangible assets
and share based payment charges.
Consolidated Balance Sheet
as at 30 September 2018
At 30 Sept At 31 March At 30 Sept
2018 2018 2017
GBP GBP GBP
Assets
Non-current assets
Intangibles 15,740,459 15,029,448 16,802,856
Property, plant and equipment 1,667,085 1,712,933 2,963,325
Deferred taxation 1,287,785 1,250,082 1,920,968
Total non-current assets 18,695,329 17,992,463 21,687,149
------------ ------------ -----------
Current assets
Inventories 1,110,767 1,823,961 2,540,365
Trade and other receivables 2,692,975 2,969,410 3,493,787
Deferred consideration 375,000 - -
Cash and cash equivalents - 115,719 2,418,441
Total current assets 4,178,742 4,909,090 8,452,593
------------ ------------ -----------
Total assets 22,874,071 22,901,553 30,139,742
------------ ------------ -----------
Equity and liabilities
Issued capital 19,797,343 19,797,343 19,801,937
Retained earnings (1,621,745) (2,685,469) 4,933,873
Other reserves 40,887 10,282 60,445
Total equity 18,216,485 17,122,156 24,796,255
------------ ------------ -----------
Liabilities
Non-current liabilities
Long term borrowings 136,100 728,830 845,741
Deferred taxation 1,748,247 1,619,795 1,999,029
Deferred income 481,752 357,360 452,065
Retirement benefit deficit - 317,294 57,199
Total non-current liabilities 2,366,099 3,023,279 3,354,034
------------ ------------ -----------
Current liabilities
Trade and other payables 1,719,507 2,602,069 1,837,707
Bank overdraft 452,200 - -
Short term borrowings 103,082 154,049 151,746
Tax payable 16,698 - -
Total current liabilities 2,291,487 2,756,118 1,989,453
------------ ------------ -----------
Total liabilities 4,657,586 5,779,397 5,343,487
------------ ------------ -----------
Total equity and liabilities 22,874,071 22,901,553 30,139,742
------------ ------------ -----------
Consolidated Statement of Changes in Equity for the six months ended
30 September 2018
Share Share Retained Translation
capital premium earnings reserve Total
GBP GBP GBP GBP GBP
Balance at 1
April 2017 5,086,756 11,640,760 4,753,190 (22,770) 21,457,936
------------------ ---------- ----------- ------------ ------------ ------------
Issue of share
capital for
cash
consideration 728,536 2,548,049 3,276,585
Expenses in
connection with
share issue - (202,164) - - (202,164)
Profit for the
period to
30 September
2017 - - 168,948 - 168,948
Other
comprehensive
income-net
exchange
adjustments - - - 83,215 83,215
Other
comprehensive
income-tax
charge - - (15,160) - (15,160)
------------------ ---------- ----------- ------------ ------------ ------------
Total
comprehensive
income 728,536 2,345,885 153,788 83,215 3,311,424
Share-based
payments - - 26,895 - 26,895
Balance at 30
September
2017 5,815,292 13,986,645 4,933,873 60,445 24,796,255
------------------ ---------- ----------- ------------ ------------ ------------
Issue of share
capital for
cash
consideration - (11,675) (11,675)
Expenses in
connection with
share issue - 7,081 - - 7,081
Loss for the
period to 31
March 2018 - - (7,438,545) - (7,438,545)
Other
comprehensive
income-net
exchange
adjustments - - - (50,163) (50,163)
Other
comprehensive
income-actuarial
loss on defined
benefit
pensions - - (258,449) - (258,449)
Other
comprehensive
income-tax
credit - - 52,277 - 52,277
------------------ ---------- ----------- ------------ ------------ ------------
Total
comprehensive
income - (4,594) (7,644,717) (50,163) (7,699,474)
Share-based
payments - - 25,375 - 25,375
Balance at 1
April 2018 5,815,292 13,982,051 (2,685,469) 10,282 17,122,156
------------------ ---------- ----------- ------------ ------------ ------------
Profit for the
period to
30 September
2018 - - 721,554 - 721,554
Other
comprehensive
income-net
exchange
adjustments - - - 30,605 30,605
Other
comprehensive
income-Omega
GmbH liability
write off 317,294 - 317,294
Other
comprehensive
income-tax
charge - - (5,124) - (5,124)
------------------ ---------- ----------- ------------ ------------ ------------
Total
comprehensive
income - - 1,033,724 30,605 1,064,329
Share-based
payments - - 30,000 - 30,000
Balance at 30
September
2018 5,815,292 13,982,051 (1,621,745) 40,887 18,216,485
------------------ ---------- ----------- ------------ ------------ ------------
Consolidated Cash Flow Statement
for the six months ended 30 September 2018
6 months 6 months
to 30 Sept to 30 Sept
2018 2017
GBP GBP
Cash flows generated from operations
Profit for the period after exceptional
items 721,554 168,948
Adjustments for:
Taxation 102,324 (96,267)
Finance costs 25,599 27,061
Finance income (11) (480)
---------------------------------------------- ------------ ------------
Operating profit after exceptional items 849,466 99,262
Decrease/(increase) in trade and other
receivables 276,435 (1,033,371)
Decrease/(increase) in inventories 86,371 (162,790)
(Decrease)/increase in trade and other
payables (1,211,411) 74,748
Depreciation 192,999 206,478
Amortisation of intangible assets 90,047 118,345
Movements in grants 124,392 119,293
Exceptional item-Gain on sale of legacy
infectious disease business (1,091,808) -
Exceptional item-Omega GmbH liabilities
write off (358,819) -
Share-based payments 30,000 26,895
---------------------------------------------- ------------ ------------
Net cash flow from operating activities (1,012,328) (551,140)
Investing activities
Finance income 11 480
Purchase of property, plant and equipment (231,262) (178,546)
Purchase of intangible assets (1,034,153) (1,204,655)
Sale proceeds from legacy infectious disease
business 1,800,000 -
Net cash used in investing activities 534,596 (1,382,721)
---------------------------------------------- ------------ ------------
Financing activities
Finance costs (25,599) (27,061)
Proceeds from issue of share capital - 3,276,585
Expenses of share issue - (202,164)
New finance leases 40,500 626,489
Drawdown of overdraft facility 452,200 -
Finance lease repayments (69,529) (78,255)
Net cash from financing activities 397,572 3,595,594
---------------------------------------------- ------------ ------------
Net (Decrease)/increase in cash and cash
equivalents (80,160) 1,661,733
Effects of exchange rate movements (35,559) 19,377
Cash and cash equivalents at beginning
of period 115,719 737,331
Cash and cash equivalents at end of period - 2,418,441
---------------------------------------------- ------------ ------------
Notes to the Interim Report
for the six months ended 30 September 2018
1. BASIS OF PREPARATION
For the purpose of preparing the March 2018 annual financial statements the Directors used IFRS as adopted by the EU and in accordance with the AIM Rules issued by the London Stock Exchange. In preparing these interim financial statements, the accounting policies used in the Group's Annual Report for the year ended 31 March 2018 have been applied consistently. The Group does not expect the adoption of IFRS9 and IFRS15 to have a material impact on the consolidated financial statements for the year ended 31 March 2019. The Group has not applied IAS 34 Interim Financial Reporting, which is not mandatory for AIM companies, in the preparation of these interim financial statements.
The interim financial statements are unaudited. The information shown in the consolidated balance sheet as at 31 March 2018 does not constitute statutory accounts as defined in Section 435 of the Companies Act 2006 and has been extracted from the Group's 2018 Annual Report which has been filed with the Registrar of Companies. The report of the auditors on the financial statements contained within the Group's 2018 Annual Report was unqualified and did not contain a statement under sections 498 (2) and 498 (3) of Chapter 3, Part 16 of the Companies Act 2006. These interim financial statements were approved by the Board of Directors on 30 November 2018.
2. SEGMENT INFORMATION
For management purposes the Group is organised into three operating divisions: Allergy and Autoimmune, Food Intolerance and Infectious Disease and Other.
The Allergy and Autoimmune division specialises in the research, development, production and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases.
The Food Intolerance division specialises in the research, development and production of kits to aid the detection of immune reactions to food. It also provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer Food Detective test.
The Infectious Diseases division specialises in the research, development and production and marketing of kits to aid the diagnosis of infectious diseases.
Corporate consists of centralised corporate costs which are not allocated across the three business divisions.
Inter segment transfers or transactions are entered into under the normal commercial conditions that would be available to unrelated third parties.
Business segment Allergy Food Infectious/
information and
Autoimmune Intolerance Other Corporate Group
September 2018 GBP GBP GBP GBP GBP
--------------------- ---------------- ------------ ------------ ------------ ------------
Statutory
presentation
--------------------- ---------------- ------------ ------------ ------------ ------------
Revenue 787,273 3,891,702 650,663 - 5,329,638
Inter-segment
revenue - (56,239) (45,864) - (102,103)
Total revenue 787,273 3,835,463 604,799 - 5,227,535
Operating costs (1,086,345) (2,438,096) (1,261,312) (1,042,943) (5,828,696)
Operating
profit/(loss)
before exceptional
items (299,072) 1,397,367 (656,513) (1,042,943) (601,161)
Exceptional items 358,819 - 1,091,808 - 1,450,627
Net finance
income/(costs) - - (5,390) (20,198) (25,588)
Profit/(loss) before
taxation 59,747 1,397,367 429,905 (1,063,141) 823,878
--------------------- ---------------- ------------ ------------ ------------ ------------
Adjusted profit
before
taxation
--------------------- ---------------- ------------ ------------ ------------ ------------
Profit/(loss) before
taxation 59,747 1,397,367 429,905 (1,063,141) 823,878
Exceptional items (358,819) - (1,091,808) - (1,450,627)
Amortisation of
intangible
assets 26,389 53,502 10,156 - 90,047
Share-based payment
charges - - - 30,000 30,000
Adjusted
profit/(loss)
before taxation (272,683) 1,450,869 (651,747) (1,033,141) (506,702)
--------------------- ---------------- ------------ ------------ ------------ ------------
Operating profit
before
exceptional items (299,072) 1,397,367 (656,513) (1,042,943) (601,161)
Depreciation 28,854 117,903 46,243 - 193,000
Amortisation 26,389 53,502 10,156 - 90,047
EBITDA (243,829) 1,568,772 (600,114) (1,042,943) (318,114)
--------------------- ---------------- ------------ ------------ ------------ ------------
Allergy Food Infectious/
and
Autoimmune Intolerance Other Corporate Group
September 2017 GBP GBP GBP GBP GBP
--------------------- ---------------- ------------ ------------ ------------ ------------
Statutory
presentation
Revenue 1,719,453 4,921,908 1,417,556 - 8,058,917
Inter-segment
revenue (44,406) (790,128) (111,048) - (945,582)
Total revenue 1,675,047 4,131,780 1,306,508 - 7,113,335
Operating costs (1,944,753) (2,648,262) (1,410,184) (1,010,874) (7,014,073)
Operating
profit/(loss) (269,706) 1,483,518 (103,676) (1,010,874) 99,262
Net finance
income/(costs) (180) (1,614) (7,291) (17,496) (26,581)
Profit/(loss) before
taxation (269,886) 1,481,904 (110,967) (1,028,370) 72,681
--------------------- ---------------- ------------ ------------ ------------ ------------
Adjusted profit
before
taxation
--------------------- ---------------- ------------ ------------ ------------ ------------
Profit/(loss) before
taxation (269,886) 1,481,904 (110,967) (1,028,370) 72,681
Amortisation of
intangible
assets 60,008 50,583 7,754 118,345
Share-based payment
charges - - - 26,895 26,895
Adjusted
profit/(loss)
before taxation (209,878) 1,532,487 (103,213) (1,001,475) 217,921
--------------------- ---------------- ------------ ------------ ------------ ------------
Operating profit
before
exceptional items (269,706) 1,483,518 (103,676) (1,010,874) 99,262
Depreciation 51,939 108,004 46,536 - 206,479
Amortisation 60,008 50,583 7,754 - 118,345
EBITDA (157,759) 1,642,105 (49,386) (1,010,874) 424,086
--------------------- ---------------- ------------ ------------ ------------ ------------
3. REVENUES 6 months 6 months
to 30 Sept to 30 Sept
2018 2017
GBP GBP
---------------- ---- ------------ ------------ ------------ ------------ ----------------------
UK 358,438 528,360
Germany 578,907 1,414,805
Rest of Europe 1,403,651 1,737,219
North America 794,926 1,309,177
South/Central
America 368,294 267,166
Asia and Far
East 1,212,662 1,033,877
Africa and Middle
East 510,657 822,731
5,227,535 7,113,335
--------------------- ------------ ------------ ------------ ------------ ----------------------
4. FINANCE COSTS
6 months 6 months
to 30 to 30
Sept Sept
2018 2017
GBP GBP
--------------------------------------- --------- ---------
Interest payable on
loans 21,594 18,984
Finance charges payable under finance
leases 4,005 8,077
25,599 27,061
--------------------------------------- --------- ---------
5. TAX (CHARGE) / CREDIT
6 months 6 months
to 30
to 30 Sept Sept
2018 2017
GBP GBP
------------------------------------------------------ ---- ----------- -------------
Tax (charged) / credited in the
income statement
Current tax - current (16,698) -
year
Current tax - prior year adjustment - -
Deferred tax - current year (111,408) 67,053
Deferred tax - prior year adjustment 25,782 29,214
(102,324) 96,267
---- ------------------------------------------------------ ----------- -------------
Tax relating to items charged to other comprehensive
income
Deferred tax on net exchange
adjustments (5,124) (15,160)
(5,124) (15,160)
---- ------------------------------------------------------ ----------- -------------
Reconciliation of total tax
charge
Factors affecting the tax charge
for the period:
Profit before tax 823,878 72,681
------------------------------------------------------- --- ----------- -------------
Effective rate of taxation 19% 19%
Profit before tax multiplied by the
effective rate of tax 156,537 13,809
Effects of:
Expenses not deductible for tax and income
not chargeable to tax 37,135 12,620
Deferred tax asset on losses in year not recognised 110,090 -
Research and development
tax credits (48,632) (51,270)
Tax over provided in prior
years (25,782) (29,214)
Adjustment due to different overseas
tax rate (39,610) (33,201)
Exceptional item-Omega GmbH liabilities
write off (68,176) -
Impact of UK rate change on deferred
tax (19,238) (9,011)
Tax charge / (credit) for
the period 102,324 (96,267)
------------------------------------------------------- --- ----------- -------------
The deferred tax asset balance at 30 September 2018 will be offset against future profits expected to be generated from the prospects for Allergy sales and Visitect(R) CD4 sales leading management to conclude to carry the deferred tax asset in full.
6. EARNINGS PER SHARE
6 months 6 months
to 30 Sept to 30 Sept
2018 2017
------------------------------------------- -------------- --------------
GBP GBP
Profit attributable to equity holders
of the Group 721,554 168,948
2018 2017
Number Number
------------------------------------------- -------------- --------------
Weighted average number of shares 126,959,060 112,378,395
Share options 306,718 1,381,285
------------------------------------------- -------------- --------------
Diluted weighted average number of shares 127,265,778 113,759,680
------------------------------------------- -------------- --------------
The number of shares in issue at the period end was 126,959,060. Basic earnings per share are calculated by dividing profit for the year attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the year.
Diluted earnings per share are calculated by dividing the profit attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. Diluting events are excluded from the calculation when the average market price of ordinary shares is lower than the exercise price.
Adjusted Earnings per share on profit for the period
The Group presents adjusted earnings per share which is calculated by taking adjusted profit before taxation and adding the tax credit in order to allow shareholders to understand better the elements of financial performance in the year, so as to facilitate comparison with prior periods and to assess better trends in financial performance.
6 months 6 months
to 30 Sept to 30 Sept
2018 2017
-------------------------------------------- ------------ ------------
GBP GBP
Adjusted (loss) / profit before taxation (506,702) 217,921
Tax (charge) / credit (102,324) 96,267
-------------------------------------------- ------------ ------------
Adjusted (loss) / profit attributable
to equity holders of the Group (609,026) 314,188
-------------------------------------------- ------------ ------------
7. INTANGIBLES
Licences/ Supply Technology Customer Development
Goodwill software arrangements assets relationships costs Total
GBP GBP GBP GBP GBP GBP GBP
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
Cost
At 1 April
2017 4,703,165 1,765,753 533,836 2,150,731 1,245,524 7,872,250 18,271,259
Additions - - - - - -
Additions
internally
generated - - - - - 1,247,225 1,247,225
Currency
translation 42,510 4,484 16,769 5,520 47,904 18,517 135,704
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
At 30
September
2017 4,745,675 1,770,237 550,605 2,156,251 1,293,428 9,137,992 19,654,188
Additions - 25,505 - - - - 25,505
Additions
internally
generated - - - - - 1,643,461 1,643,461
Currency
translation (4,052) (855) (1,598) (532) (15,350) (5,516) (27,903)
Asset write
offs (1,391,745) (172,101) (549,007) (180,725) (1,178,075) (1,589,722) (5,061,375)
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
At 31 March
2018 3,349,878 1,622,786 - 1,974,994 100,003 9,186,215 16,233,876
Additions - (114) - - - 1,092,267 1,092,153
Additions - - - - - - -
internally
generated
Disposals (332,986) - - - - - (332,986)
Currency
translation 17,608 14,902 6,946 2,286 14,904 7,133 63,779
At 30
September
2018 3,034,500 1,637,574 6,946 1,977,280 114,907 10,285,615 17,056,822
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
Accumulated
amortisation
At 1 April
2017 - 218,604 533,836 1,114,046 816,697 - 2,683,183
Amortisation
charge
in the year - 10,103 - 49,374 60,649 - 120,126
Currency
translation - 5,049 16,769 5,268 20,937 - 48,023
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
At 30
September
2017 - 233,756 550,605 1,168,688 898,283 - 2,851,332
Amortisation
charge
in the year - 5,491 - 49,374 57,231 6,249 118,345
Currency
translation - (523) (1,598) (502) (653) (359) (3,635)
Asset write
offs - (179,399) (549,007) (172,460) (854,858) (5,890) (1,761,614)
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
At 31 March
2018 - 59,325 - 1,045,100 100,003 - 1,204,428
Amortisation
charge
in the year - 8,513 - 49,374 24,538 7,622 90,047
Currency
translation - 2,111 6,946 2,182 11,130 (481) 21,888
At 30
September
2018 - 69,949 6,946 1,096,656 135,671 7,141 1,316,363
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
Net book
value
30-Sep-18 3,034,500 1,567,625 - 880,624 (20,764) 10,278,474 15,740,459
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
31-Mar-18 3,349,878 1,563,461 - 929,894 - 9,186,215 15,029,448
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
30-Sep-17 4,745,675 1,536,481 - 987,563 395,145 9,137,992 16,802,856
-------------- ------------ ---------- ------------- ----------- -------------- ------------ ------------
8. GAIN ON SALE OF LEGACY INFECTIOUS DISEASE BUSINESS
On the 28(th) of June 2018 the Group sold its legacy infectious disease business to Lab21 Healthcare Limited for up to GBP2.175 million. The consolidated statement of comprehensive income includes the following gain on sale:
GBP
---------------------------- ----------
Consideration to be
received 2,175,000
Assets disposed
of :
Intangible assets -
goodwill 332,986
Property, plant and
equipment 50,383
Inventories 626,823
Legal fees associated with
the disposal 73,000
Gain on sale through the
income statement 1,091,808
------------------------------- ----------
9. DISCONTINUED OPERATIONS
6 month period ended 30 Sept 6 month period ended 30 Sept
2018 2017
Omega India Infectious Omega India Infectious
Gmbh Manufacturing Disease TOTAL Gmbh Manufacturing Disease TOTAL
GBP GBP GBP GBP GBP GBP GBP GBP
Revenue 578,907 - 423,739 1,002,646 1,422,119 - 1,155,997 2,578,116
Cost of sales 221,610 12,664 229,862 464,136 584,285 55,213 610,767 1,250,265
---------- -------------- ----------- ---------- ---------- -------------- ----------- ----------
Gross profit 357,297 (12,664) 193,877 538,510 837,834 (55,213) 545,230 1,327,851
Administration
costs 397,840 38,363 4,671 440,874 438,419 152,368 25,942 616,729
Selling and
marketing
costs 195,205 - - 195,205 451,348 - - 451,348
---------- -------------- ----------- ---------- ---------- -------------- ----------- ----------
Operating
(loss)
/ profit (235,748) (51,027) 189,206 (97,569) (51,933) (207,581) 519,288 259,774
Finance costs - - - - - - - -
---------- -------------- ----------- ----------
Profit before
taxation (235,748) (51,027) 189,206 (97,569) (51,933) (207,581) 519,288 259,774
Amortisation 24,573 - - 24,573 59,217 - - 59,217
Adjusted (loss)
profit for the
period (211,175) (51,027) 189,206 (72,996) 7,284 (207,581) 519,288 318,991
---------- -------------- ----------- ---------- ---------- -------------- ----------- ----------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR BDBDDUDGBGID
(END) Dow Jones Newswires
December 03, 2018 02:00 ET (07:00 GMT)
1 Year Omega Diagnostics Chart |
1 Month Omega Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
